Article ; Online: Radiation countermeasure agents: an update (2011-2014).
Expert opinion on therapeutic patents
2014 Volume 24, Issue 11, Page(s) 1229–1255
Abstract: ... of existing agents since 2011 and new agents identified as radiation countermeasure for ARS during this period ... towards the development of a safe, nontoxic and effective radiation countermeasure for the acute radiation syndrome (ARS ... no drug has been approved by the US FDA. A radiation countermeasure to protect the population ...
| Abstract | Introduction: Despite significant scientific advances over the past 60 years towards the development of a safe, nontoxic and effective radiation countermeasure for the acute radiation syndrome (ARS), no drug has been approved by the US FDA. A radiation countermeasure to protect the population at large from the effects of lethal radiation exposure remains a significant unmet medical need of the US citizenry and, thus, has been recognized as a high priority area by the government. Area covered: This article reviews relevant publications and patents for recent developments and progress for potential ARS treatments in the area of radiation countermeasures. Emphasis is placed on the advanced development of existing agents since 2011 and new agents identified as radiation countermeasure for ARS during this period. Expert opinion: A number of promising radiation countermeasures are currently under development, seven of which have received US FDA investigational new drug status for clinical investigation. Four of these agents, CBLB502, Ex-RAD, HemaMax and OrbeShield, are progressing with large animal studies and clinical trials. G-CSF has high potential and well-documented therapeutic effects in countering myelosuppression and may receive full licensing approval by the US FDA in the future. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Acute Radiation Syndrome/prevention & control ; Animals ; Cytokines/pharmacology ; Cytokines/therapeutic use ; Humans ; Patents as Topic ; Radiation-Protective Agents/pharmacology ; Radiation-Protective Agents/therapeutic use ; United States ; United States Food and Drug Administration | |||||
| Chemical Substances | Cytokines ; Radiation-Protective Agents | |||||
| Language | English | |||||
| Publishing date | 2014-10-14 | |||||
| Publishing country | England | |||||
| Document type | Journal Article ; Review | |||||
| ZDB-ID | 1186201-4 | |||||
| ISSN | 1744-7674 ; 0962-2594 ; 1354-3776 | |||||
| ISSN (online) | 1744-7674 | |||||
| ISSN | 0962-2594 ; 1354-3776 | |||||
| DOI | 10.1517/13543776.2014.964684 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 3962: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.